Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 31;21(21):8178.
doi: 10.3390/ijms21218178.

Prevention of Diabetes and Cardiovascular Disease in Obesity

Lucia La Sala  1 , Antonio E Pontiroli  2
Affiliations
Review

Prevention of Diabetes and Cardiovascular Disease in Obesity

Lucia La Sala et al. Int J Mol Sci. .

Abstract

Obesity is one of the major risk factors for the development of both impaired glucose tolerance (IGT, or prediabetes) and type 2 diabetes (T2D), and its prevalence worldwide drives toward an increased rate of cardiovascular morbidity and mortality. Given the estimations of the World Health Organization (WHO) and the recommendation of the Diabetes Prevention Program (DPP), where IGT and diabetes are considered as risk factors for the development of cardiovascular complications and obesity, the development of diabetes should be treated because of its potential reversibility. In this view, several interventions such as diet, lifestyle changes, and pharmacological treatment are effective, including bariatric metabolic surgery (BMS), which is the most incisive way to efficiently lower body weight. In this review, we sought to summarize some of the major aspects linked to diabetes prevention in overweight/obesity, focusing on the use of surgery; we also attempted to elucidate molecular pathways involved in a variety of obesity-induced processes able to favor the progression of chronic diseases, such as diabetes and its complications.

Keywords: CVD; T2D; atherosclerosis; cardiovascular complications; diabetes; inflammation; metabolic syndrome; microRNA; obesity; prevention.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure A1
Figure A1
Major contributors of T2D/Obesity driving toward to dysregulation of target tissues.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abarca-Gómez L., Abdeen Z., Hamid Z.A., Abu-Rmeileh N.M., Acosta-Cazares B., Acuin C., Adams R.J., Aekplakorn W., Afsana K., Aguilar-Salinas C., et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642. doi: 10.1016/S0140-6736(17)32129-3. - DOI - PMC - PubMed
    1. Schnurr T.M., Jakupović H., Carrasquilla G.D., Ängquist L., Grarup N., Sørensen T.I.A., Tjønneland A., Overvad K., Pedersen O., Hansen T., et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: A case-cohort study. Diabetology. 2020;63:1324–1332. doi: 10.1007/s00125-020-05140-5. - DOI - PubMed
    1. Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900,000 adults: Collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–1096. doi: 10.1016/S0140-6736(09)60318-4. - DOI - PMC - PubMed
    1. Pontiroli A.E., Pizzocri P., Librenti M.C., Vedani P., Marchi M., Cucchi E., Orena C., Paganelli M., Giacomelli M., Ferla G., et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: A three-year study. J. Clin. Endocrinol. Metab. 2002;87:3555–3561. doi: 10.1210/jcem.87.8.8708. - DOI - PubMed
    1. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study. BMJ. 1983;287:867–870. doi: 10.1136/bmj.287.6396.867. - DOI - PMC - PubMed